ORENITRAM (treprostinil)

SELF ADMINISTRATION-ORAL 

Indications of Prior Authorization:

  • Indicated in adults for the treatment of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 to improve exercise capacity.

Patients must meet the following criteria for the indication(s) above:

  • Patient is 18 of years or older, AND
  • Diagnosis of WHO Group 1 PAH confirmed by chart note documentation, AND 
  • Prescribed by or in consultation with a cardiologist or pulmonologist, AND
  • Patient has had a right heart catheterization with results confirming diagnosis of WHO Group 1 PAH confirmed by chart note documentation, AND
  • Patient has tried two oral therapies for PAH from other categories (either alone or in combination) each for ≥ 60 days: PDE5 Inhibitors (e.g. Revatio, Adcirca), ERA (e.g. Tracleer, Letairis, or Opsumit), or Adempas, OR
  • Patient is receiving or has received prostacyclin therapy for PAH in the past (e.g. Tyvaso, Ventavis, Remodulin, or epoprostenol injection-Flolan, Veletri) or a prostacyclin receptor agonist (e.g. Uptravi) for PAH. 

Dosing:

  • 0.25 mg by mouth every 12 hours with food or 0.125 mg every 8 hours with food; may increase dose in increments of 0.25 mg or 0.5 mg every 1 hours or 0.125 mg every 8 hours every 3-4 days as tolerated.

Approval: 

  • 1 year 

Last review date: February 24, 2020

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone